IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Dudley et al. Customer No. : 11030

Serial No. : 10/829,618 Confirmation No. : 7286

Filed : 4/20/2004 Group Art Unit : 1627

Examiner : Jean-Louis, Samira

For : Androgen Pharmaceutical Composition and Method for Treating

Depression

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Applicants hereby submit the present Supplemental Information Disclosure Statement in the application noted above. Enclosed herewith for consideration by the U.S. Patent and Trademark Office is a listing of a substantive final office action in a related family member. Applicants note that in the Supplemental IDS submitted on January 12, 2011, an incorrect serial no. was listed for this entry. Applicants hereby correct the entry with the present submission.

This Information Disclosure Statement is submitted according to the following selected paragraph(s):

This Information Disclosure Statement is being filed under 37 C.F.R. §1.97(b) (1) within three months of the filing date of a national application other than a continued prosecution application under 37 C.F.R. § 1.53(d); (2) within three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application; (3) before the mailing of a first Office action on the merits; or (4) before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. § 1.114.

| | a final action or a notice of allowance. Payment for the fee required by 37 C.F.R. §1.97(c) prior to either | |
|--|---|--|
| | is here | by authorized to be charged to Deposit Account No. 02-4377. |
| | | information Disclosure Statement is being filed under 37 C.F.R. §1.97(c), with a ment under, 37 C.F.R. §1.97(e) prior to either a final action or a notice of allowance. |
| | The undersigned hereby states that (check one): | |
| | | each item of information contained in the information disclosure statement was first |
| | | cited in any communication from a foreign patent office in a counterpart foreign |
| | | application not more than three months prior to the filing of the information |
| | | disclosure statement. |
| | | no item of information contained in the information disclosure statement was cited in |
| | | a communication from a foreign patent office in a counterpart foreign application, |
| | | and, to the knowledge of the person signing the certification after making reasonable |
| | | inquiry, no item of information contained in the information disclosure statement |
| | | was known to any individual designated in 37 C.F.R. § 1.56(c) more than three |
| | | months prior to the filing of the information disclosure statement. |
| | This Information Disclosure Statement is being filed under 37 C.F.R. §1.97(d), with a | |
| | statem | ent under 37 C.F.R. §1.97(e), after a final action or a notice of allowance but prior to |
| | payme | ent of the issue fee. Payment for the fee required by 37 C.F.R. §1.17(p) is hereby |
| | author | ized to be charged to Deposit Account No. 02-4377. The undersigned hereby |
| | petitio | ns that this Information Disclosure Statement be considered prior to issuance of the |
| | patent | . The undersigned hereby states that (check one): |
| | | each item of information contained in the information disclosure statement was first |
| | | cited in any communication from a foreign patent office in a counterpart foreign |
| | | application not more than three months prior to the filing of the information |
| | | disclosure statement. |
| | | no item of information contained in the information disclosure statement was cited in |
| | | a communication from a foreign patent office in a counterpart foreign application, |
| | | and, to the knowledge of the person signing the certification after making reasonable |
| | | inquiry, no item of information contained in the information disclosure statement |

months prior to the filing of the information disclosure statement.

☐ The references listed on the accompanying PTO-1449 were either cited by the Examiner or previously submitted in parent application U.S. Serial No. _______, filed _______Pursuant to 37 C.F.R. § 1.98(d), the references are not required if the earlier application is identified and relied upon for an effective filing date under 35 U.S.C. § 120 and therefore are not enclosed herewith.

☐ Related Application Disclosure

☐ Applicants would like to bring to the attention of the Examiner the following related patent applications, which are also listed on the accompanying PTO-1449:

☐ Disclosure of Office Actions and Responses in Related Applications

☐ Applicants would like to bring to the attention of the Examiner the following Office Actions issued in related patent applications and Responses to Office Actions filed in such applications, which are also listed on the accompanying PTO-1449:

was known to any individual designated in 37 C.F.R. § 1.56(c) more than three

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that the listed documents are material or constitute "prior art." If the Examiner applies the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of the documents.

12-30-2010 Final Rejection

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should the documents be applied against the claims of the present application.

12/543,541

Applicants believe no fee is due in connection with this submission. However, if any fee is due, or if any overpayment has been made, the Commissioner is authorized to charge any such fee or credit any overpayment to our Deposit Account No. 02-4377.

Respectfully submitted,

Burcha Lee

Date: January 26, 2011

Sandra S. Lee Patent Office Reg. No. 51,932

Daniel Hulseberg Patent Office Reg. No. 36,554

Baker Botts L.L.P. CUSTOMER NO. 11030

30 Rockefeller Plaza 44th Floor New York, NY 10012-4498 Attorney for Applicant(s) 212-408-2500